The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Measurable residual disease (MRD) negativity was associated with better response to treatment with the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) in
The Japan Ministry of Health, Labour and Welfare has approved epcoritamab (Epkinly) as a treatment for adult patients with relapsed or refractory follicular
Axicabtagene ciloleucel (axi-cel) prolonged survival in large B-cell lymphoma (LBCL) compared with standard of care (SOC), and the ZUMA-7 trial also found that
Which therapies in top-line data show potential benefits for anemia compared to expected levels with JAK inhibition.
SOHO will hold its first regional meeting in Spain from February 27-28, 2025, at the Rafael del Pino Auditorium in Madrid. The program
Prophylactic dexamethasone did not improve the safety or efficacy of axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphoma (LBCL), according to a
Researchers assessed barriers to chimeric antigen receptor (CAR) T-cell therapy for patients with non-Hodgkin lymphoma (NHL) in a community-based network and found that
FDA accepts for review a BLA for Blenrep in combination with bortezomib plus dexamethasone and pomalidomide plus dexamethasone in MM.
A study showed that the triplet therapy isatuximab, pomalidomide, and dexamethasone (IsaPd) is an option for daratumumab-refractory multiple myeloma (MM), though the “modest”
By: Phillip McLeod The European Commission (EC) has approved blinatumomab (Blincyto) as a consolidation therapy for adult patients newly diagnosed with Philadelphia chromosome-negative,
